ALLO
ALLO
Company information not available. Track real-time insider trading activity, SEC Form 4 filings, and executive stock transactions.
Insider Buys
0
$0
Insider Sales
1
$49K
Total Volume
$49K
1 transactions
Net Activity
$49K
Net selling
Sentiment Rating
Moderate DistributionCEO Conviction Index
No Recent Signal
Key Drivers
- •Heavy distribution: sales represent 100% of total transaction value.
Score Methodology
The Insider Confidence Score (1-100) measures executive conviction. Starting from a neutral 50, it adjusts based on:
- +15Strong Buy Ratio: Purchases > 70% of volume (or up to -15 for heavy sales).
- +20Cluster Buying: ≥3 unique insiders buying within a 30-day window.
- +15CEO Buying: CEO committing own capital shows high conviction.
- +10CFO Buying: CFO purchasing shares shows financial alignment.
Parker Geoffrey M.
CFO
$49K total
Quick Actions
ALLO has an insider buy conviction of 0%, compared to the Unknown sector buy average of 6%.
Over the last 90 days, corporate insiders at ALLO (ALLO) engaged in a total of 1 transactions reported via SEC Form 4 filings. Among these, 0 were open-market purchases and 1 were sales. The total volume of insider trading reached $49K.
The net insider activity for ALLO shows a net selling bias of $49K. This activity represents a 0% buy ratio, suggesting that insiders are currently bearish on the company's near-term outlook relative to recent history.
The most notable individual transaction was a Sale by Parker Geoffrey M. (CFO), who traded 36.3K shares valued at $49K on Oct 21, 2026.
Is Allogene Therapeutics (ALLO) Stock Outpacing Its Medical Peers This Year?
Allogene: If MRD Holds, This Becomes A Completely Different Company
Allogene stock sails after CAR T clears residual lymphoma in early data cut
Allogene Therapeutics (ALLO) Down 11.1% Since Last Earnings Report: Can It Rebound?
ALLO Stock Soars As ALPHA3 Trial Data Reset Expectations
$ALLO stock is up 11% today. Here's what we see in our data.
Related News & Analyst Reports
Read original insights and educational research covering ALLO and the Unknown sector.
The Spinoff Separation: Tracking Post-Spinoff Executive Ownership Trends
An investigation of corporate spinoffs, showing how executive equity allocations and post-separation insider transactions signal parent and subsidiary performance trajectories.
Rule 10b5-1 Trading Plans: What Investors Need to Know
Rule 10b5-1 plans allow insiders to pre-schedule trades while aware of material information, but the 2023 SEC reforms added mandatory cooling-off periods. This guide explains the new rules and what changed for investors tracking insider activity.
Insider Buying vs. Stock Buybacks: Which Signal Should You Follow?
Corporate buybacks and insider purchases are both bullish signals — but they differ fundamentally in what they mean, how reliable they are, and how you should incorporate them into your investment analysis. This guide breaks down the mechanics, academic research, and practical applications of both signals.
Rule 10b5-1 Trading Plans: What Every Investor Must Know
Rule 10b5-1 plans allow corporate insiders to pre-schedule stock sales months in advance, providing them with an affirmative defense against insider trading allegations. This guide explains how these plans work, why they matter for interpreting insider transaction data, and the significant regulatory changes made by the SEC in 2023.
Institutional Ownership vs. Insider Holdings: Who Has More Influence?
When BlackRock and Vanguard own 15% of a company and the CEO owns 0.5%, whose incentives drive capital allocation decisions? This report compares activist institutional pressure against insider ownership depth as governance indicators.
FAQs About ALLO Insider Trading
Answers to common questions regarding corporate filings and executive sentiment for ALLO.